Bluejay Diagnostics, Inc. (BJDX)
NASDAQ: BJDX · Real-Time Price · USD
1.870
+0.010 (0.54%)
At close: Mar 9, 2026, 4:00 PM EDT
1.840
-0.030 (-1.60%)
After-hours: Mar 9, 2026, 6:33 PM EDT

Company Description

Bluejay Diagnostics, Inc. operates as a medical diagnostics company.

The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components.

It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis.

In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings.

Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure.

Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Bluejay Diagnostics, Inc.
Bluejay Diagnostics logo
Country United States
Founded 2015
IPO Date Nov 10, 2021
Industry Medical Devices
Sector Healthcare
Employees 5
CEO Indranil Dey

Contact Details

Address:
360 Massachusetts Avenue, Suite 203
Acton, Massachusetts 01720
United States
Phone 844 327 7078
Website bluejaydx.com

Stock Details

Ticker Symbol BJDX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $10.00
CIK Code 0001704287
CUSIP Number 095633608
ISIN Number US0956336087
Employer ID 47-3552922
SIC Code 3841

Key Executives

Name Position
Indranil Dey Principal Financial, Accounting and Executive Officer, President, Chief Executive Officer and Director
Kevin Vance Chief Commercial Officer
Mark W. Feinberg M.D., Ph.D. Chief Medical Advisor
Dr. Mark W. Feinberg M.D. Chief Medical Advisor

Latest SEC Filings

Date Type Title
Mar 6, 2026 10-K Annual Report
Mar 6, 2026 8-K Current Report
Feb 20, 2026 8-K Current Report
Feb 18, 2026 SCHEDULE 13G Filing
Feb 18, 2026 8-K Current Report
Feb 17, 2026 SCHEDULE 13G Filing
Feb 13, 2026 SCHEDULE 13G/A Filing
Feb 5, 2026 SCHEDULE 13G Filing
Feb 5, 2026 SCHEDULE 13G Filing
Jan 30, 2026 8-K Current Report